TNFRSF11A and osteoporosis: Based on these interesting results implicating the RANKL/RANK interaction in dystrophic myocardium integrity, and given that denosumab has been approved by the FDA for the treatment of osteoporosis, we investigated the possibility that our observations could be translated to patients affected by DMD.